Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

Meanwhile, there was more encouraging news for the UK's science base after it emerged that the country's research teams have won £500 million in research grants from the EU after being excluded from ...

That is according to the chief executive of the American Association for the Advancement of Science (AAAS), Sudip Parikh, who ...

PT: How does pharma deal with diverse geographies during launch? AH: This is difficult! Local and national reimbursement environments vary significantly by country and many will reference ...

Pharmaceutical companies approach a significant wave of patent expirations by 2030. This includes exclusivity rights set to expire for 569 medications valued at $278 billion, based on 2022 sales.

An artificial intelligence-powered tool for triaging patients with suspicious skin lesions, developed by Skin Analytics, will be used by the NHS to reduce waiting times. DERM (Deep Ensemble for ...

The US federal government intends to spend $500 million on a project to develop universal vaccines that can protect against multiple virus variants at the same time. That's the conclusion of an ...

Pursue advocacy efforts We’ve seen critical legal decisions over the last five years either accelerate or stymie the United States biosimilar market. In the 2017 Amgen v. Sandoz case, the ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies. One important piece of the puzzle that ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.